Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010
Introduction
The myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal haematopoietic stem cell disorders characterised by ineffective hematopoiesis and an increased risk of leukaemic transformation [1]. At the beginning of the new millennium, the World Health Organization (WHO) classified MDS as malignant myeloid neoplasms [2], [3], and consequently MDS became reportable malignancies to population-based cancer registries as of 2001. The age-standardised incidence rate (ASR) of MDS is currently 2.0 to 3.4 per 100,000 in Western countries and the incidence increases sharply with older age [4], [5], [6], [7], [8]. Life expectancy of patients with MDS is variable and is dependent on the MDS subtype, and several clinical and prognostic parameters [9], [10], [11], [12], [13]. Treatment decisions also rely on clinical and prognostic parameters [14], [15], [16].
Recent clinical studies have reported favourable outcomes in patients with MDS after treatment with immunomodulatory agents (e.g. lenalidomide [17] or hypomethylating agents (i.e. azacitidine [18] and decitabine [19]. Survival data derived from clinical trials can be biased, however, because of patient selection (e.g. exclusion of elderly patients with comorbidities) [20]; therefore, inference about the general patient population might not be made. The availability of nationwide population-based studies with long-term follow-up on incidence and survival in an unselected MDS population are lacking. In the few reported population-based studies on incidence and survival in MDS, the period of patient inclusion was short and the follow-up period was limited [4], [5], [6], [21]. Furthermore, population-based studies regarding treatment decision in the entire MDS population have not been reported previously.
We have performed a nationwide population-based study in more than 5000 newly diagnosed patients with MDS in the Netherlands from 2001 to 2010 reported to the Netherlands Cancer Registry (NCR). The aim of this study was to assess trends in incidence, initial treatment and survival among these MDS patients.
Section snippets
The Netherlands Cancer Registry
Established in 1989, the population-based nationwide NCR is maintained and hosted by the Comprehensive Cancer Centres. The NCR is based on notifications of all newly diagnosed malignancies in the Netherlands by the automated nationwide archive of histopathology and cytopathology (PALGA), to which all pathological laboratories report. The NCR also receive notifications from the national registry of hospital discharges and various haematology departments. Information on date of birth, sex, date
Results
We identified a total of 5144 newly diagnosed patients with MDS during the study period (Table 1). Their median age at diagnosis was 74 years and 86% were 60 years of age or older at diagnosis. Regarding the subtypes of MDS, 486 (9%) were classified as RA, 583 (11%) RARS, 82 (2%) the 5q-syndrome, 524 (10%) RCMD, 966 (19%) RAEB, while 2503 (49%) were unspecified (Table 1). The proportion of unspecified MDS decreased from 60% in 2001 to 36% in 2010 (data not shown). The annually reported number of
Discussion
To our knowledge, this is the first nationwide population-based study reporting incidence, initial treatment and survival among newly diagnosed patients with MDS during a 10-year period since MDS were formally classified as malignant neoplasms in 2001.
The data are consistent with a rise in the annually reported number of MDS patients throughout the study period. However, the annual ASR has stabilised since 2007; the initial rise is presumably due to better case ascertainment and classification
Conflict of interest statement
None declared.
Acknowledgements
The authors would like to thank the registration clerks of the Netherlands Cancer Registry for the dedicated data collection. The authors also would like to thank the Dutch-Belgian Hemato-Oncology Group (HOVON) for support during the study.
This work was supported by grants from The Netherlands Organization for Health Research and Development (ZonMw) and Celgene B.V., The Netherlands.
References (36)
Myelodysplastic syndromes
Blood
(2008)- et al.
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs
Blood
(2008) - et al.
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
Blood
(2010) - et al.
Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry
Leuk Res
(2011) - et al.
International scoring system for evaluating prognosis in myelodysplastic syndromes
Blood
(1997) - et al.
Revised international prognostic scoring system for myelodysplastic syndromes
Blood
(2012) - et al.
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
Leuk Res
(2010) - et al.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Lancet Oncol
(2009) - et al.
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Blood
(2013) - et al.
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes
Semin Hematol
(2008)
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
Blood
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference
Leuk Res
International classification of diseases for oncology
Pathology and genetics of tumours of haematopoietic and lymphoid tissues
Myelodysplastic syndromes: incidence and survival in the United States
Cancer
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
Br J Cancer
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
J Clin Oncol
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Cancer
Cited by (49)
Hematologic malignancies of primary bone marrow involvement: a decade's experience in Bahrain
2023, Hematology, Transfusion and Cell TherapyCitation Excerpt :The overall ASIR per 100,000 per year for MDS in our study (0.85) suggests an increasing trend, compared to the previous report in Bahrain (0.7) (Figure 2).1 Increasing trends of MDS over time were reported in the US and Europe and this might be attributed to the improved diagnosis and reporting of these malignancies. 27,29 The MM was the third most common primary hematologic malignancy in our study.
Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world
2023, Journal of Geriatric OncologyIncidence of myelodysplastic syndromes in Finland 1997–2016
2022, Leukemia ResearchCitation Excerpt :This has also led to paucity of studies on MDS incidence. Previous studies of the incidence of MDS, in the Netherlands, Germany, Switzerland and the USA, have reported overall age-standardized incidence rate (ASIR) ranging 2.5–3.4 per 100,000 person-years [11–14]. A large study based on 44 different cancer registries estimated that the ASIR of MDS in Europe years 2000–2002 was 1.24 per 100,000 person-years [15].
- 1
A.G.D. and O.V. contributed equally to this study.